10x Genomics (Nasdaq: TXG) today announced it will report financial results for the first quarter 2020 after market close on Monday, May 11, 2020. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.10
PLEASANTON, Calif., April 24, 2020 (GLOBE NEWSWIRE) -- 10X Genomics (Nasdaq: TXG) today announced it will report financial results for the first quarter 2020 after market close on Monday, May 11, 2020. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.10xgenomics.com. The webcast will be archived and available for replay for at least 45 days after the event.
About 10x Genomics
10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including 96 of the top 100 global research institutions and 19 of the top 20 global pharmaceutical companies, and have been cited in over 700 research papers on discoveries ranging from oncology to immunology and neuroscience. The company’s patent portfolio comprises more than 700 issued patents and patent applications.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Contacts
Investors
investors@10xgenomics.com
Media
media@10xgenomics.com
